{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:32:27Z","timestamp":1786350747654,"version":"build-2736575974"},"reference-count":74,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Locally advanced non-small cell lung cancer (NSCLC) is a biologically and clinically heterogeneous disease in which mediastinal lymph node involvement remains the principal prognostic and therapeutic discriminator. Accurate nodal staging guides selection among surgical resection, definitive chemoradiotherapy, immunotherapy, and targeted therapy. This narrative review synthesizes contemporary evidence on mediastinal staging modalities, nodal disease burden, and treatment selection in stage II-III NSCLC. Contemporary staging integrates CT and FDG-PET\/CT with systematic tissue confirmation using EBUS-TBNA and EUS, with surgical mediastinal staging reserved for selected high-risk or discordant cases. The ninth edition TNM N2a\/N2b distinction, increasing use of neoadjuvant and perioperative immunotherapy, and molecularly guided therapy have further amplified the clinical consequences of under- or over-staging. Nodal assessment should therefore be interpreted through a multidisciplinary framework that integrates anatomy, biology, treatment response, and patient operability.<\/jats:p>","DOI":"10.3390\/cancers18162561","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:08:53Z","timestamp":1786349333000},"page":"2561","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nodal Staging in Patients with Locally Advanced Non-Small Cell Lung Cancer: Indications, Approaches, and Impact on Downstream Treatment Selection"],"prefix":"10.3390","volume":"18","author":[{"given":"Ido","family":"Haimi","sequence":"first","affiliation":[{"name":"Department of Thoracic & Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2782-7756","authenticated-orcid":false,"given":"Ravi","family":"Rajaram","sequence":"additional","affiliation":[{"name":"Department of Thoracic & Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","article-title":"The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer","volume":"119","author":"Kim","year":"2024","journal-title":"Ann. Thorac. Surg."},{"key":"ref_3","unstructured":"(2026, April 28). Non-Small Cell Lung Cancer. National Comprehensive Cancer Network. Updated 2026-03-13. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"108073","DOI":"10.1016\/j.lungcan.2024.108073","article-title":"Prognostic impact of the N2 subclassification and stage migration in the ninth edition of the TNM classification in surgically resected lung cancer","volume":"199","author":"Nakao","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jtho.2024.04.002","article-title":"Validation Study for the N Descriptor of the Newly Proposed Ninth Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer","volume":"19","author":"Kim","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Son, J.W., Lee, J., Jeon, J.H., Cho, S., Jung, W., Shih, B.C.-H., Kim, K., and Jheon, S. (2024). Validation of IASLC 9th edition TNM classification for lung cancer: Focus on N descriptor. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13139-z"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sassorossi, C., Chiappetta, M., Lococo, F., Santoro, G., Novellis, P., Veronesi, G., Di Fonzo, R., Gallina, F.T., Facciolo, F., and Aprile, V. (2026). Validation of the 9th Edition of the TNM Classification in Patients with NSCLC and Lymph Node Involvement: A Retrospective, Multicentric, Observational Study. Cancers, 18.","DOI":"10.3390\/cancers18040702"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/wjs.70241","article-title":"A New N2 Descriptor for Resectable Non-Small Cell Lung Cancer: The Classification Based on Skip Metastasis and the Number of N2 Station Involvement","volume":"50","author":"Huang","year":"2026","journal-title":"World J. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.cllc.2023.06.007","article-title":"Non\u2013Small Cell Lung Cancer With N1 Involvement or Skip Metastases Presents the Same Survival Outcome: Results From a Multicentric Study","volume":"24","author":"Chiappetta","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Schlachtenberger, G., Schallenberg, S., Doerr, F., Menghesha, H., Gaisendrees, C., Amorin, A., Grathwohl, C., B\u00fcttner, R., Quaas, A., and Horst, D. (2022, January 5\u20138). Do skip-N2 metastases significantly impact overall survival and disease-free interval in N2 non-small-cell lung cancer patients? A multicentre analysis. Proceedings of the 36th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery (EACTS), Milan, Italy.","DOI":"10.1093\/ejcts\/ezad247"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ejso.2019.12.015","article-title":"Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients","volume":"46","author":"Li","year":"2020","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wang, S., Xie, S., Han, Y., Gao, M., Su, X., and Liu, Q. (2023). Role of skip N2 lymph node metastasis for patients with the stage III-N2 lung adenocarcinoma: A propensity score matching analysis. BMC Pulm. Med., 23.","DOI":"10.1186\/s12890-023-02437-0"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/j.cllc.2020.02.027","article-title":"Skip N2 Metastasis in Pulmonary Adenocarcinoma: Good Prognosis Similar to N1 Disease","volume":"21","author":"Wang","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e211S","DOI":"10.1378\/chest.12-2355","article-title":"Methods for Staging Non-small Cell Lung Cancer","volume":"143","author":"Silvestri","year":"2013","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of Stage III Non\u2013Small-Cell Lung Cancer: ASCO Guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1007\/s00259-025-07177-3","article-title":"Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET\/CT","volume":"52","author":"Mingels","year":"2025","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_17","first-page":"E37","article-title":"Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography\/computed tomography for the detection of metastases in non\u2013small-cell lung cancer patients","volume":"132","author":"Wu","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Shen, G., Lan, Y., Zhang, K., Ren, P., and Jia, Z. (2017). Comparison of 18F-FDG PET\/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176150"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.2015.2365","article-title":"FDG-PET\/CT Imaging for Mediastinal Staging in Patients With Potentially Resectable Non\u2013Small Cell Lung Cancer","volume":"313","author":"Baldwin","year":"2015","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"818.e17","DOI":"10.1016\/j.crad.2019.07.009","article-title":"Improving diagnostic performance of 18F-FDG-PET\/CT for assessment of regional nodal involvement in non-small cell lung cancer","volume":"74","author":"Yang","year":"2019","journal-title":"Clin. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1007\/s00330-024-11036-4","article-title":"Diagnostic accuracy of CT and PET\/CT radiomics in predicting lymph node metastasis in non-small cell lung cancer","volume":"35","author":"Li","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Xu, R., Wang, K., Peng, B., Zhou, X., Wang, C., Lu, T., Shi, J., Zhao, J., and Zhang, L. (2024). Evaluating peritumoral and intratumoral radiomics signatures for predicting lymph node metastasis in surgically resectable non-small cell lung cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1427743"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41598-023-28242-7","article-title":"Artificial intelligence-based radiomics for the prediction of nodal metastasis in early-stage lung cancer","volume":"13","author":"Shimada","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/mp.16177","article-title":"Predicting N2 lymph node metastasis in presurgical stage I-II non-small cell lung cancer using multiview radiomics and deep learning method","volume":"50","author":"Zhang","year":"2023","journal-title":"Med. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.21037\/jtd-22-1511","article-title":"Artificial intelligence neural network analysis and application of CT imaging features to predict lymph node metastasis in non-small cell lung cancer","volume":"14","author":"Geng","year":"2022","journal-title":"J. Thorac. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.21037\/jtd-23-1578","article-title":"A comparison of machine learning methods for radiomics modeling in prediction of occult lymph node metastasis in clinical stage IA lung adenocarcinoma patients","volume":"16","author":"Liu","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Erdogdu, E., \u00d6ks\u00fcz, I., Duman, S., Ozkan, B., Erturk, S.M., Bakkalo\u011flu, D.V., Kara, M., and Toker, A. (2025). Machine learning-based prediction of N2 lymph node metastasis in non-small cell lung cancer. BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03921-5"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1378\/chest.15-1216","article-title":"Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report","volume":"149","author":"Wahidi","year":"2016","journal-title":"Chest"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.21037\/jtd-2025-1202","article-title":"A comprehensive review of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): Staging, techniques, and future directions","volume":"17","author":"Fiore","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(24)00010-9","article-title":"Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): An international, multicentre, single-arm, clinical trial","volume":"12","author":"Steinfort","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2488","DOI":"10.1097\/MD.0000000000002488","article-title":"Systematic Endobronchial Ultrasound-guided Mediastinal Staging Versus Positron Emission Tomography for Comprehensive Mediastinal Staging in NSCLC Before Radical Radiotherapy of Non-small Cell Lung Cancer","volume":"95","author":"Steinfort","year":"2016","journal-title":"Medicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1245\/s10434-025-18551-8","article-title":"Systematic Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) Compared with Targeted EBUS-TBNA for Mediastinal Staging of Locally Advanced Non-small Cell Lung Cancer","volume":"33","author":"Fajardo","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16180","article-title":"Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: Results from the ASTER randomised controlled trial","volume":"16","author":"Sharples","year":"2012","journal-title":"Health Technol. Assess."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.athoracsur.2016.05.110","article-title":"Endosonography Versus Mediastinoscopy in Mediastinal Staging of Lung Cancer: Systematic Review and Meta-Analysis","volume":"102","author":"Sehgal","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"ref_35","first-page":"3805","article-title":"Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial","volume":"41","author":"Bousema","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2600097","DOI":"10.1183\/13993003.00097-2026","article-title":"ERS\/ESGE\/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer","volume":"68","author":"Korevaar","year":"2026","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.7150\/jca.119881","article-title":"The Prognostic Value of Lymph Node Downstaging Following Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer","volume":"16","author":"Guo","year":"2025","journal-title":"J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107401","DOI":"10.1016\/j.lungcan.2023.107401","article-title":"Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"186","author":"Huang","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis","volume":"20","author":"Marinelli","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-025-01768-1","article-title":"PACIFIC-5: A phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","volume":"18","author":"Wu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2021.39.15_suppl.8511","article-title":"Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial","volume":"39","author":"Spigel","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.21.01774","article-title":"Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer","volume":"40","author":"Levy","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non\u2013Small Cell Lung Cancer: The Phase III PACIFIC-2 Study","volume":"43","author":"Bradley","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2023.41.16_suppl.8521","article-title":"Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs. C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial","volume":"41","author":"Spicer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"LBA8511","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA8511","article-title":"Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB\u2013IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816","volume":"40","author":"Spicer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.22.02509","article-title":"US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non\u2013Small-Cell Lung Cancer","volume":"41","author":"Akinboro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.annonc.2025.11.017","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: Final analysis of the randomized RATIONALE-315 trial","volume":"37","author":"Wang","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1002\/cncr.35357","article-title":"Top advances of the year: Perioperative therapy for lung cancer","volume":"130","author":"Aredo","year":"2024","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"LBA8035","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8035","article-title":"IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after \u22655 years of follow up of a phase III study of adjuvant atezolizumab vs. best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC)","volume":"42","author":"Wakelee","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtcvs.2023.04.039","article-title":"The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non\u2013small cell lung cancer","volume":"166","author":"Kidane","year":"2023","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO-24-01681","article-title":"Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non\u2013Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial","volume":"43","author":"Felip","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_59","unstructured":"U.S. Food and Drug Administration (2026). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), U.S. Food and Drug Administration. [46th ed.]."},{"key":"ref_60","first-page":"358","article-title":"Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide","volume":"73","author":"Fox","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e70286","DOI":"10.1002\/cncr.70286","article-title":"Minimal residual disease in solid tumors: Clinical applications and future directions","volume":"132","author":"Abdo","year":"2026","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/jnci\/djaf061","article-title":"Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)","volume":"117","author":"Xia","year":"2025","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108528","DOI":"10.1016\/j.lungcan.2025.108528","article-title":"ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach","volume":"203","author":"Rosenlund","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e2500489","DOI":"10.1200\/PO-25-00489","article-title":"Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non\u2013Small Cell Lung Cancer: An Updated Meta-Analysis","volume":"9","author":"Lu","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-Based Molecular Residual Disease Detection for Non\u2013Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)","volume":"28","author":"Xia","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/cncr.35263","article-title":"Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer","volume":"130","author":"Tan","year":"2024","journal-title":"Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: Ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14737159.2023.2252334","article-title":"Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer","volume":"23","author":"Xia","year":"2023","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"103800","DOI":"10.1016\/j.critrevonc.2022.103800","article-title":"Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer","volume":"179","author":"Li","year":"2022","journal-title":"Crit. Rev. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/cncr.33985","article-title":"Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non\u2013small cell lung cancer","volume":"128","author":"Li","year":"2021","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Fang, X., Yu, S., Jiang, Y., Xiang, Y., and Lu, K. (2022). Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1027664"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2025.1115","article-title":"Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non\u2013Small Cell Lung Cancer","volume":"11","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"108879","DOI":"10.1016\/j.lungcan.2025.108879","article-title":"Multiomic analysis of treatment-na\u00efve NSCLC before the era of neoadjuvant immunotherapy reveals contrasting immune phenotypes in stage IIIA: Node-dominant (T1N2) exhibiting hot versus tumor-dominant (T4N0) cold features","volume":"211","author":"Kim","year":"2025","journal-title":"Lung Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2561\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:20:07Z","timestamp":1786350007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":74,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162561"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162561","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}